An In-silico Approach: Design, Homology Modeling, Molecular Docking, MM/GBSA Simulations, and ADMET Screening of Novel 1,3,4-oxadiazoles as PLK1inhibitors.

Q3 Medicine
Sindhya Malkaje, Mahendra Gowdru Srinivasa, Shridhar Deshpande N, Suharsha Navada, Revanasiddappa Bc
{"title":"An <i>In-silico</i> Approach: Design, Homology Modeling, Molecular Docking, MM/GBSA Simulations, and ADMET Screening of Novel 1,3,4-oxadiazoles as PLK1inhibitors.","authors":"Sindhya Malkaje,&nbsp;Mahendra Gowdru Srinivasa,&nbsp;Shridhar Deshpande N,&nbsp;Suharsha Navada,&nbsp;Revanasiddappa Bc","doi":"10.2174/2589977514666220821203739","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most commonly diagnosed and major cause of cancer-related deaths in women worldwide. Disruption of the normal regulation of cell cycle progression and proliferation are the major events leading to cancer. Human Polo-like Kinase 1 (PLK1) plays an important role in the regulation of cellular division. High PLK1 expression is observed in various types of cancer including breast cancer. 1,3,4-oxadiazoles are the fivemembered heterocycles, that serve as versatile lead molecules for designing novel anticancer agents and they mainly act by inhibiting various enzymes and kinases.</p><p><strong>Objective: </strong>A novel series of 1,3,4-oxadiazole derivatives (A1-A26) were designed and subjected to an in-silico analysis against PLK1 enzyme (PDB ID:1q4k), targeting breast cancer.</p><p><strong>Methods: </strong>The chemical structure of each compound (A1-26) was drawn using ChemDraw software. The 3D structure model of protein target (PDB ID:1q4k) was built using the SWISSMODEL server. Molecular docking simulation was performed to determine the designed compound's probable binding mode and affinity towards the protein target (PDB ID:1q4k). The designed compounds were subjected to ADME screening, as well as Prime MM/GBSA simulations using Schrodinger suite 2020-4. Furthermore, the safety profile of compounds was examined through the OSIRIS property explorer program and the results were compared with the standard drugs, 5-fluorouracil and cyclophosphamide.</p><p><strong>Results: </strong>Based on the binding affinity scores, the compounds were found selective to target protein 1q4k through hydrogen bonding and hydrophobic interactions. The compounds A11, A12, and A13 were found to have higher G scores and binding free energy values. The ADME screening results were also found to be within the acceptable range. Moreover, the in-silico toxicity prediction assessments suggest that all designed compounds have a low risk of toxicity, and have higher efficiency for the target receptor.</p><p><strong>Conclusion: </strong>The study showed that the substitution of electron-donating groups at the various position of the aromatic ring, which is bonded at the second position of the substituted 1,3,4- oxadiazole nucleus resulted in compounds with good binding energy and G score compared to the standard drugs, and hence, they can be further developed as potent PLK1 enzyme inhibitors.</p>","PeriodicalId":37008,"journal":{"name":"Current Drug Research Reviews","volume":"15 1","pages":"88-100"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Research Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2589977514666220821203739","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Breast cancer is the most commonly diagnosed and major cause of cancer-related deaths in women worldwide. Disruption of the normal regulation of cell cycle progression and proliferation are the major events leading to cancer. Human Polo-like Kinase 1 (PLK1) plays an important role in the regulation of cellular division. High PLK1 expression is observed in various types of cancer including breast cancer. 1,3,4-oxadiazoles are the fivemembered heterocycles, that serve as versatile lead molecules for designing novel anticancer agents and they mainly act by inhibiting various enzymes and kinases.

Objective: A novel series of 1,3,4-oxadiazole derivatives (A1-A26) were designed and subjected to an in-silico analysis against PLK1 enzyme (PDB ID:1q4k), targeting breast cancer.

Methods: The chemical structure of each compound (A1-26) was drawn using ChemDraw software. The 3D structure model of protein target (PDB ID:1q4k) was built using the SWISSMODEL server. Molecular docking simulation was performed to determine the designed compound's probable binding mode and affinity towards the protein target (PDB ID:1q4k). The designed compounds were subjected to ADME screening, as well as Prime MM/GBSA simulations using Schrodinger suite 2020-4. Furthermore, the safety profile of compounds was examined through the OSIRIS property explorer program and the results were compared with the standard drugs, 5-fluorouracil and cyclophosphamide.

Results: Based on the binding affinity scores, the compounds were found selective to target protein 1q4k through hydrogen bonding and hydrophobic interactions. The compounds A11, A12, and A13 were found to have higher G scores and binding free energy values. The ADME screening results were also found to be within the acceptable range. Moreover, the in-silico toxicity prediction assessments suggest that all designed compounds have a low risk of toxicity, and have higher efficiency for the target receptor.

Conclusion: The study showed that the substitution of electron-donating groups at the various position of the aromatic ring, which is bonded at the second position of the substituted 1,3,4- oxadiazole nucleus resulted in compounds with good binding energy and G score compared to the standard drugs, and hence, they can be further developed as potent PLK1 enzyme inhibitors.

新型plk1抑制剂1,3,4-恶二唑的设计、同源性建模、分子对接、MM/GBSA模拟和ADMET筛选
背景:乳腺癌是全世界妇女癌症相关死亡的最常见诊断和主要原因。破坏细胞周期进程和增殖的正常调节是导致癌症的主要事件。人polo样激酶1 (PLK1)在细胞分裂调控中起重要作用。PLK1在包括乳腺癌在内的多种癌症中均有高表达。1,3,4-恶二唑是一类五元杂环化合物,是设计新型抗癌药物的多用途先导分子,主要通过抑制多种酶和激酶起作用。目的:设计了一系列新的1,3,4-恶二唑衍生物(A1-A26),并进行了针对乳腺癌的PLK1酶(PDB ID:1q4k)的硅质分析。方法:采用ChemDraw软件绘制化合物(A1-26)的化学结构。利用SWISSMODEL服务器建立蛋白靶点(PDB ID:1q4k)的三维结构模型。通过分子对接模拟确定所设计化合物可能的结合模式和对蛋白靶点(PDB ID:1q4k)的亲和力。设计的化合物进行了ADME筛选,并使用薛定谔套件2020-4进行了Prime MM/GBSA模拟。此外,通过OSIRIS属性探索者程序检查化合物的安全性,并将结果与标准药物5-氟尿嘧啶和环磷酰胺进行比较。结果:根据结合亲和力评分,发现化合物通过氢键和疏水相互作用选择性靶向蛋白1q4k。化合物A11、A12和A13具有较高的G值和结合自由能值。ADME筛选结果也在可接受范围内。此外,硅毒性预测评估表明,所有设计的化合物具有较低的毒性风险,并且对靶受体具有较高的效率。结论:本研究表明,在取代的1,3,4-恶二唑核的第2位键合的芳香环上不同位置的供电子基团的取代得到的化合物与标准药物相比具有良好的结合能和G分数,因此可以进一步开发为有效的PLK1酶抑制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Drug Research Reviews
Current Drug Research Reviews Medicine-Psychiatry and Mental Health
CiteScore
3.70
自引率
0.00%
发文量
38
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信